drug · protein
sargramostim
Phase 3updated 3mo agoby Partner Therapeutics Inc🔗 ChEMBL
Phase 3community read0 votes
Protein drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 42 investigational indications.
targets
Granulocyte-macrophage colony-stimulating factor receptor
all catalysts(0)
nothing on the calendar yet
Trials studying sargramostim
- phase1Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
- phase1SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
- phase2Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease
- phase1Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease
- phase1MIBG With Dinutuximab +/- Vorinostat
- phase2UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
- phase3A Phase II/III Study of Sargramostim
- phase2Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that